Eli Lilly’s obesity treatment “Munzaro” surpassed its rival product “Wigobi” in the cumulative numbe..

detail

*It has been translated using AI
Eli Lilly’s obesity treatment “Munzaro” surpassed its rival product “Wigobi” in the cumulative number of prescriptions 10 months after it was released in Korea. Competition for high-dose products and next-generation new drugs is also in full swing as it quickly dominates the market with excellent <a href="https://healthylife7.com/eu-approves-novel-fibre-to-help-prevent-weight-gain/” title=”EU Approves Novel Fibre to Help Prevent Weight Gain”>weight loss effects. However, more than half of the prescriptions were concentrated in their 20s and 30s, and the number of prescriptions for teenagers has increased 1.5 times this year, raising concerns about misuse.
◆ The cumulative number of prescriptions is also overtaken by Hugo Bee
According to the Drug Safety Use Service (DUR) data submitted by Han Ji-ah, a member of the People’s Power, from the Health Insurance Review and Assessment Service on the 29th, 1.51,161 cases of Mountaineer were prescribed for 10 months from August last year to May this year when it was released in Korea. The number of monthly prescriptions increased 14.7 times from 18,579 in the first month of release to 273,140 in May this year. The cumulative number of prescriptions (1,228,867) for Hugo Bee, which was released about a year earlier, has also exceeded.
It is analyzed that the relatively high weight loss effect has affected the growth of Mountaineer. In a direct comparative clinical trial (SURMOUNT-5), Mounzaro recorded an average weight loss rate of 20.2%, exceeding the Hugo ratio (13.7%). The monthly treatment cost based on the starting capacity is also about 280,000 won for Mountaineer and 210,000 won for Hugo, so the satisfaction level is high compared to the effectiveness. By age, prescriptions in their 20s and 30s accounted for 52.9% of the total. Those in their 30s accounted for 36.0%, followed by those in their 40s (27.1%), those in their 20s (16.9%), and those in their 50s (14.6%). The number of teen prescriptions also increased from 82 in August last year to 2,594 in May this year.
◆ “A medicine to lose weight.” Don’t blind faith
The medical community believes that young people’s demand for beauty purposes is significant as Maunzaro and Hugo Bee, which are treatments for diabetes or highly obese patients, are simply recognized as “fat-loss drugs.” Glucagon-like peptide-1 (GLP-1) obesity treatments are mainly prescribed by patients with a BMI of 25 or higher, a BMI of 23 or higher, and weight-related comorbidities such as diabetes and high blood pressure. However, it is known that there are not a few prescriptions for cosmetic purposes in the medical field.
Yoon, who has lost 7kg to the mountain in the last two months, said, “I was prescribed the mountain by the so-called holy place of internal medicine, and I weighed myself with a 10kg dumbbell that the nurse gave me,” adding, “I went there just because I wanted to lose 5kg ahead of the summer vacation, but it wasn’t difficult to get a prescription.”
Prescriptions for people in their 60s and older are also increasing rapidly. By June this year, the number of prescription checks for people aged 60 or older in Hugo Bee and Mountaineer was 104,327. However, the medical community believes that the proportion of prescriptions for the management of comorbid diseases such as diabetes and high blood pressure and weight loss is higher in the elderly than for cosmetic purposes.
◆ The obesity drug war will continue
The Ministry of Food and Drug Safety is considering designating Hugo Bee and Mountaineer as drugs of concern for misuse. The Korean Diabetes Association recently said, “GLP-1 receptor agonists are prescription drugs that should be used according to the medical judgment of experts,” adding that improper use can limit treatment opportunities for patients who need actual treatment. Currently, the obesity drug market has expanded from touching only GLP-1, a hormone that suppresses appetite, like Hugo Bee, to a double agent that touches GLP-1 and GIP hormones that help secrete insulin at the same time like Maunzaro. Recently, Eli Lilly and Hanmi Pharmaceutical are speeding up the development of next-generation candidates that work in triplicate. In the past, if obesity drugs only pressed one ‘switch’ to suppress appetite, double and triple agents can be understood as a way to lose more weight by increasing energy consumption or pressing two or three switches at once to help control blood sugar.
Meanwhile, competition between Mountaineer and Hugo Bee is also spreading to high-capacity products. Korea Lily launched 12.5mg and 15mg products in June, and has a capacity lineup before being licensed in Korea. Novo Nordisk has started to expand its market by obtaining permission in the United States and Europe for “Wigobi HD” (7.2mg), which has a higher capacity than before.
[Reporter Wang Hae Na]
#

Most Read News

• 1
  

  While the government is expected to come up with a real estate tax reform plan as early as next mont

• 2
  

  In the cryptocurrency (virtual asset) market, a single abnormal transaction of leveraged derivatives

  3 Hours ago
• 3
  

  Moon Geun-young, the beloved former child star, has married musical and theater actor Jeong Pyeong

  8 Hours ago

• 4
  

  In an apartment, the sewage pipe was blocked by 40kg of rice, causing the sewage to flow back to the

  2026.07.28 10:33

• 5
  

  Recently, as videos of artificial intelligence (AI) weathercasters delivering weather spread online

  2026.07.28 14:35

• 6
  

  The KOSPI, which had plunged the previous day, plunged nearly 6% on the 29th, eventually giving up t

  2 Hours ago

• 7
  

  Who is actor Jeong Pyeong, 46, the man who won over the heart of ‘the nation’s little sister’ Moon G

  6 Hours ago

• 8
  

  Citi Securities, a global investment bank, estimated that domestic individual investors lost about $

  3 Hours ago

• 9
  

  The Constitutional Court has made a constitutional decision on the provisions of the Civil Code, whi

  2026.07.28 07:35

• 10
  

  Individual investors are increasingly afraid of the domestic stock market, which has repeated its sl

  8 Hours ago

IVE’s Jang Won-young made her presence felt on the Major League Baseball (MLB) stage.On the 28th, Ja

Actor Kim Hye-soo showed off her dazzling beauty.On the 21st, Kim Hye-soo posted several photos on I

Photo | Arena Homme Plus Group Tomorrow X Together’s Taehyun revealed the behind-the-scenes story of

Actor Kim Yoo-jung has made a bold transformation with blonde hair.According to her agency Awesome E

Minami of the group Rescene attended the opening ceremony of the “Character Licensing Fair • Board G